Cite
HARVARD Citation
Smith, M. et al. (2022). Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet oncology. 23 (3), pp. 362-373. [Online].